Comparison of sertraline and venlafaxine treatments for depression in Parkinson's disease;Parkinson hastalıǧı'nda depresyon için sertralin ve venlafaksin tedavisinin karşılaştırılması

Noropsikiyatri Arsivi

Volumn 48, Issue 3, 2011, Pages 201-206

  Akça, Alp ^a   Mehmet, A K ^b   Sütçügil, Levent ^b   ÖZ̧ahin, Aytekin ^b   Kütükçü, Yaşar ^b  

^a Erzincan Asker Hastanesi   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Depression; Parkinson's disease; Sertraline; Venlafaxine

Indexed keywords

ANTIPARKINSON AGENT; SERTRALINE; VENLAFAXINE;

ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MEMORY; MINI MENTAL STATE EXAMINATION; ORIENTATION; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; UKU SIDE EFFECT RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

EID: 80054855477     PISSN: 13000667     EISSN: None     Source Type: Journal    
DOI: 10.4274/Npa.Y5711     Document Type: Article

References (43)

1. Beucke JC, Uhl I, Plotkin M et al. Serotonergic neurotransmission in early Parkinson's disease: A pilot study to assess implications for depression in this disorder. World J Biol Psychiatry 2010; 11:781-7.
2. Warburton JW. Depressive symptoms in Parkinson's patients referred for thalamotomy. J Neurol Neurosurg Psychiatry 1967; 30:368-70.
3. Goetz CG. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord 2010; 25(Suppl 1):104-9.
4. Menza MA, Mark MH. Parkinson disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci 1994; 6:165-9.
5. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease: a community-based study. Arch Neurol 1996; 53:175-9.
6. Leentjens AF, Lousberg R, Verhey FR. Markers for depression in Parkinson's disease. Acta Psychiatr Scand 2002; 106:196-201.
7. Kuopio AM, Marttila RJ, Helenius H, et al. The quality of life in Parkinson's disease. Mov Disord 2000; 15:216-23.
8. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009; 24:2175-86.
9. Schneider F, Althaus A, Backes V et al. Psychiatric symptoms in Parkinson's disease. Eur Arch Psychiatry Clin Neurosci 2008; 258 (Suppl 5):55-9.
10. Kamrowska A. Depression in Parkinson's disease. Pol Merkur Lekarski 2009; 27:170-2.
11. Kizkin S, Atay T, Özer F et al. Parkinson hastali{dotless}ǧi{dotless}nda uyku: Bir ön çali{dotless}şma. Nöro Psikiyatri Arşivi 2000; 37:151-7.
12. Lieberman A. Depression in Parkinson's disease, a review. Acta Neurol Scand 2006; 113:1-8.
13. Slaughter JR, Slaughter KA, Nichols D et al. Prevalence, clinical manifestations, etiology and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13:187-96.
14. Corrigan M, Denahan AQ, Wright CE, et al. Comparison of pramipexole, şuoksetine and placebo in patients with major depression. Depress Anxiety 2000; 11:58-65.
15. Ceravolo R, Nuti A, Piccinni, A et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000; 55:1216-8.
16. Zesiewicz TA, Hauser RA. Depression in Parkinson's disease. Curr Psychiatry Rep 2002; 4:69-73.
17. Yazici O. Star-D sonrasi{dotless}: saǧalti{dotless}ma direnen depresyon (SDD). NöroPsikiyatri Arşivi 2009; 46:61-9.
18. Onur E, Yemez B, Cengizçetin N et al. Parkinson hastali{dotless}ǧi{dotless}'nda depresyon si{dotless}kli{dotless}ǧi{dotless} ve yaşam kalitesini etkileyen faktörler. Nöro Psikiyatri Arşivi 2007; 44:49-53.
19. Şint AJ. Pharmacologic treatment of depressionin late life. CMAJ 1997; 157:1061-7.
20. Çorapçioǧlu A, Aydemir Ö, Yildiz M et al. DSM-IV eksen 1 ruhsal bozukluklari{dotless}na göre Türkçe yapi{dotless}landi{dotless}ri{dotless}lmi{dotless}ş klinik deǧerlendirmenin güvenirliǧi. i{cyrillic, ukrainian}laç ve Tedavi Dergisi 1999; 12:33-6.
21. Akdemir A, Örsel S, Daǧ I, et al. Hamilton depresyon derecelendirme ölçeǧi (hddö)'nin geçerliǧi, güvenirliǧi ve klinikte kullani{dotless}mi{dotless}. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4:251-9.
22. Gügen C, Ertan T, Eker E et al. Standardize Mini Mental Test'in türk toplumunda hafif demans tani{dotless}si{dotless}nda geçerlik ve güvenilirliǧi. Türk Psikiyatri Dergisi 2002; 13:273-81.
23. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side efeects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100.
24. Fahn S, Elton RL, UPDRS program members. Unified Parkinsons Disease Rating Scale. Fahn S, Marsden CD, Goldstein M, Calne DB, editörler. Recent developments in Parkinsons disease, vol 2. Şorham Park, NJ: Macmillan Healthcare Information; 1987; 153-63.
25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-42.
26. Brooks DJ, Doder M. Depression in Parkinson's disease. Curr Opin Neurol 2001; 14:465-70.
27. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002; 17:445-54.
28. Leentjens AF, Lousberg R, Verhey FR. Markers for depression in Parkinson's disease. Acta Psychiatr Scand 2002; 106:196-201.
29. Kuopio AM, Marttila RJ, Helenius H, et al. The quality of life in Parkinson's disease. Mov Disord 2000; 15:216-23.
30. Huber SJ, Paulson GW, Shuutleworth EC. Depression in Parkinson's disease. Neuropsychiatry, Neuropsychologyand Behavioral Neurology 1988; 1:47-51.
31. Starkstein SE, Preziosi TJ, Bolduc PL, et al. Depression in Parkinson's disease. J Nevr Ment Dis 1990; 178:27-31.
32. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol 1995; 65:61-84.
33. Eker SS, Kirli S, Akkaya C, et al. Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women? World J Biol Psychiatry 2009; 10:400-8.
34. Gaillard R. Comparative efficacy and acceptability of new-generation antidepressants. Synthesis meta-analysis Cipriani. Encephale 2009; 35:499-504.
35. Marino S, Sessa E, Di Lorenzo G, et al. Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. Neurol Sci 2008; 29:391-5.
36. Devanand DP, Pelton GH, Marston K, et al. Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 2003; 18:123-30.
37. Mauri MC, Fiorentini A, Cerveri G, et al. Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. Hum Psychopharmacol 2003; 18:385-88.
38. Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 2006; 21:1119-22.
39. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994; 55(Suppl A):62-8.
40. Gony M, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centers. Risk of serious extrapyramidal symptoms in patients with parkinson's disease receiving antidepres- sant drug: a pharmacoepidemiologic study comparing serotonin reup- take i{dotless}nhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26:142-5.
41. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001; 24:221-7.
42. Bolukbasi O, Akyol A. Spontaneous erections and libido increase associated with venlafaxine. Eur J Neurol 1999; 6:527-8.
43. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action anti- depressants. Clin Ther 2009; 31:945-61.